Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Goldenwell Biotech Q3 2026 Results: Net Loss of $31.5K, Loss Widens

Goldenwell Biotech Inc. reported a net loss of $86,022 for the nine months ended September 30, 2026, with zero revenue generated during the period. The company faces substantial doubt about its ability to continue as a going concern due to an accumulated deficit of $1,742,138 and limited cash reserves of $788.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Gross profit0.00.0
Net income-0.0-0.0

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: GWLL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Goldenwell Biotech, Inc.: key numbers

Share price
$0.6000Close, Nov 16
Market cap
$59.4M
Shares outstanding
99MLatest SEC cover page
Sector
Manufacturing
Industry
Food and Kindred ProductsSIC 2000

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Goldenwell Biotech, Inc.

All →
9:51 AM ET 8-K
Leadership Change

Goldenwell Biotech Leadership Change

Goldenwell Biotech, Inc. appointed Ming Zhou to its board of directors, effective October 8, 2026. In connection with the appointment, CEO Shuang Liu gifted 20,000,000 shares of common stock to Ms. Zhou, representing approximately 20.2% of the company's outstanding shares.

Counterparty
Ming Zhou

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.